



Docket No. A058 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Victor Koteliansky et al.  
Serial No.: 09/734,300  
Filing Date: December 11, 2000  
For: VARIANT TYPE II TGF-BETA RECEPTOR FUSION  
PROTEINS AND METHODS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Post Office as First Class Mail addressed to BOX MISSING PARTS, Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below.

Date: June 7, 2001 Signature: Jeanne Schmitter

REQUEST FOR CORRECTION OF APPLICATION FILING RECEIPT


The Official Filing Receipt received in connection with the above-identified application contains a typographical error in the name of inventor, Victor Koteliansky. Please correct the spelling of his name as indicated on the attached copy of the Official Filing Receipt.

Please charge our deposit account 02-2327 for any deficiencies.

Respectfully submitted,

Date: 6/7/01

Niki D. Cox  
Niki D. Cox  
Reg. No. 42,446  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
(617) 679-2079



COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20531  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/734,300	12/11/2000	1633	1128	A058US		21	8

CONFIRMATION NO. 6220

## FILING RECEIPT



\*OC000000005858346\*

Biogen, Inc.  
14 Cambridge Center  
Cambridge, MA 02142

Date Mailed: 03/13/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s) *Koteliansky*  
Victor Kotelianski, Boston, MA;  
Philip Gotwals, Needham, MA;  
Richard Cate, Cohasset, MA;  
Michele Sanicola-Nadel, Winchester, MA;

## Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CON OF PCT/US99/13629 06/16/1999  
WHICH CLAIMS BENEFIT OF 60/089,452 06/16/1998

## Foreign Applications

If Required, Foreign Filing License Granted 03/08/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

## Title

Variant type II TGF-beta receptor fusion proteins and methods

Preliminary Class

424

---

Data entry by : SEDIQEE, AHMADULLAH

Team : OIPE

Date: 03/13/2001



**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231